The non-good manufacturing practice (GMP) laboratory contains two rooms that are physically separated from the U.S. Food and Drug Administration (FDA) GMP certified pilot and production areas. The new labs provide customizable, flexible systems that will expedite formulation and process development services for customers. Specifically, the facility will enable production of smaller batches using less active pharmaceutical ingredients (APIs).

The facility mirrors the company's existing pilot and production capabilities, but will also provide customers with immediate-release, modified release, taste-masked, or other custom formulation solutions through its proprietary technologies. These include:

• Microcaps for taste-masking via a solvent or aqueous-based coacervation process
• Diffucaps that incorporate release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals
• MMTS Multi Mini Tablet System in which functional membranes are applied to 1-2 mm cylindrical tablets to control release rates
• Other microspheres and microcapsules

Eurofins CDMO expands drug product operations in Canada
Eurofins contract development and manufacturing organization (CDMO) has expanded its existing drug product operation capabilities with a new manufacturing...

Samsung Biologics partners on antibody development, manufacturing
Samsung Biologics has announced that its contract development and manufacturing organization services have been selected by two companies for their antibody...